Provided by Tiger Fintech (Singapore) Pte. Ltd.

IDEAYA Biosciences

17.42
-0.7600-4.18%
Post-market: 17.420.00000.00%17:18 EDT
Volume:1.19M
Turnover:21.06M
Market Cap:1.53B
PE:-4.82
High:18.77
Open:18.04
Low:17.33
Close:18.18
Loading ...

RBC Capital Reaffirms Their Buy Rating on IDEAYA Biosciences (IDYA)

TIPRANKS
·
08 May

IDEAYA Gets FDA Clearance to Initiate Clinical Trial of Antibody Drug Conjugate Program in Solid Tumors

MT Newswires Live
·
06 May

IDEAYA Biosciences Posts Q1 Net Loss; Cash Runway Extended Through 2029

MT Newswires Live
·
06 May

IDEAYA Biosciences Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
06 May

BRIEF-IDEAYA Biosciences Announces US FDA IND-Clearance For IDE849, A Potential First-In-Class DLL3 TOP1 ADC, For A Phase 1 Study In Solid Tumors

Reuters
·
06 May

IDEAYA Biosciences Q1 EPS $(0.82) Misses $(0.67) Estimate

Benzinga
·
06 May

Earnings Flash (IDYA) IDEAYA Biosciences Posts Q1 Net Loss $0.82, vs. FactSet Est of $0.66 Loss

MT Newswires Live
·
06 May

IDEAYA Biosciences Reports Q1 2025 Results: Net Loss Down to $72.2M, Increased G&A Expenses Amid Pipeline Support

Reuters
·
06 May

IDEAYA Biosciences Q1 Operating Expenses USD 84.389 Million

THOMSON REUTERS
·
06 May

Press Release: IDEAYA Biosciences, Inc. Reports First Quarter 2025 Financial Results and Provides Business Update

Dow Jones
·
06 May

IDEAYA Biosciences Inc - to Start Phase 1 Study in U.S. Based on FDA Guidance

THOMSON REUTERS
·
06 May

IDEAYA Biosciences Announces US FDA Ind-Clearance for Ide849, a Potential First-in-Class Dll3 Top1 ADC, for a Phase 1 Study in Solid Tumors

THOMSON REUTERS
·
06 May

IDEAYA Biosciences to Participate in Upcoming May 2025 Investor Relations Events

PR Newswire
·
28 Apr

BRIEF-Ideaya Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Reuters
·
25 Apr

IDEAYA Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
25 Apr

IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

PR Newswire
·
25 Apr

IDEAYA Biosciences’ Trial Expansion and Regulatory Uncertainties Lead to Hold Rating

TIPRANKS
·
16 Apr

Mizuho Securities Sticks to Its Buy Rating for IDEAYA Biosciences (IDYA)

TIPRANKS
·
15 Apr

Ideaya trial design consisent with guidance, says Oppenheimer

TIPRANKS
·
14 Apr

Ideaya Biosciences Completes Phase 3 Trial Design Meetings With FDA; Shares Up Pre-Bell

MT Newswires Live
·
14 Apr